Result of a cooperative study with L-asparaginase in human leukemias. Report of the section "oncology" of the Paul-Ehrlich-Society for Chemotherapy.
D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001774:Blood Chemical Analysis; D001792:Blood Platelets / Q000032:analysis; D001799:Blood Sedimentation; D001835:Body Weight; D002493:Central Nervous System Diseases / Q000139:chemically induced; D003630:Daunorubicin / Q000627:therapeutic use; D004906:Erythrocyte Count; D006529:Hepatomegaly / Q000209:etiology; D006801:Humans; D007938:Leukemia / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D007958:Leukocyte Count; D009325:Nausea / Q000139:chemically induced; D013163:Splenomegaly / Q000209:etiology; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced
D014750:Vincristine; D001215:Asparaginase; D003630:Daunorubicin